Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License... (angamo is also developing sequence-speci...)

Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement

Date:10/5/2009

angamo is also developing sequence-specific ZFP Nucleases (ZFN) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to engineer cell lines for the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com.

This press release may contain forward-looking statements based on Sigma-Aldrich's and Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFNs, potential therapeutic, medical research and pharmaceutical applications of the ZFN technology and the timing of initiation of clinical trials by Sangamo. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, the ability of Sangamo and Sigma-Aldrich to develop commercially viable products and technological developments by our competitors. See the SEC filings, and in particular, the risk factors described in the Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q of each of Sangamo and Sigma-Aldrich. Neither Sigma-Aldrich nor Sangamo assumes any obligation to update the forward-looking information contained in this press release.

Sigma-Aldrich and CompoZr are trademarks of Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co. ZFP Therapeutic is a trademark of Sangamo BioSciences, Inc.

SOURCE Sigma-Aldrich Corporation

SOURCE Sigma-Aldrich Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:12/15/2009)... Reportlinker.com announces that a new market research ... The Future of Orphan Diseases ... Analysis and Reimbursement ,, ... Summary ,, The author has released ... Diseases Therapeutics - Market Forecasts to 2015, ...

(Date:12/15/2009)... Minn., Dec. 15 The Mosaic Company (NYSE: ... fiscal year 2010 earnings results and financial tables on ... on the New York Stock Exchange. Results will ... ,, The Company will host a conference call with ... the results. The call will begin at 11:00 ...

(Date:12/15/2009)... PHILADELPHIA and LONDON, Dec. 15 ... Thomson Pharma ® has become the first ... trial protocol and outcome information. This highly anticipated ... Pharma customers this month. ,, ... trial intelligence from registries, publications, press releases, conferences, ...

(Date:12/14/2009)... -- Vermillion, Inc. (Pink Sheets: VRML), a ... Wallen, Ph.D. Chief Scientific Officer, Senior Vice ... will be joining its board of directors ... ,, "Bill brings more than 20 years ... biotechnology," said Gail Page, Vermillion Executive Chairperson. ...

[0] Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement [0] Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call [0] Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials [0] Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors

... Following the,completion of the Phase II clinical development of ... end of Phase,II meeting with the FDA to discuss ... there was an open and highly constructive discussion with ... the first ever formal discussions with the,agency to license ...

... Holmes Named PartnerLONDON, March 3 Index Ventures ... stage fund, Index Ventures V. The fund is dedicated ... and clean technology sectors across Europe, the United States and ... has raised in the past ten years and reinforces the ...

... Stock Exchange Symbol: MSEDMONTON, March 2 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), announced that effective on ... purchase warrants, each of which entitles the holder to ... of $5.00 per share, will be extended from March ...

Other Biology Technology:Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting 2 Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting 3 Index Ventures Closes Euro 350 Million Early Stage Fund 2 BioMS Medical warrant extension 2

Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting Index Ventures Closes Euro 350 Million Early Stage Fund BioMS Medical warrant extension

(Date:12/15/2009)... Fla. When treating devastating brain diseases such as ... bags to find something to help a patient. , ... help the vast majority of patients with ataxia ... coordination. , University of Florida neurologists are trying to ... Challenge grant from the National Institute of Neurological Disorders ...

(Date:12/15/2009)... environmental impacts, social dynamics, and production levels are ... of an agroecosystem. Positive or negative, these factors ... social groups to continuously adapt farming and food ... learning theory suggests that knowledge is gained as ... are especially valuable for environmental and agricultural educators ...

(Date:12/15/2009)... December 2009 - Scientists at VIB and Ghent University ... the treatment of septic shock, the major cause of ... of nitric oxide (NO) gas in mice with septic ... the animal,s organs showed much less damage, while their ... expectations, since it is generally assumed that nitric oxide ...

[0] UF to lead national effort to help patients with rare brain disease [0] Experiential learning teaches change and adaptation [0] Septic shock: Nitric oxide beneficial after all

... EPA,s ocean survey vessel, the OSV BOLD, will conduct a series ... in and around the San Juan Bay Estuary, Jobos Bay, La ... also be open to the public when it docks in San ... Feb. 23, the OSV BOLD will sail to the U.S. Virgin ...

... read stories about how to "grow your own organs" using ... this breakthrough has been elusive. A new report published in ... ( http://www.fasebj.org ) brings bioengineered organs a step closer, as ... describe how they were able to use a "scaffolding" material ...

... WASHINGTON, D.C. Neuroscientists at Georgetown University Medical Center ... looks like when someone anticipates an action or sensory ... issue of the Journal of Neuroscience , they ... of the brain responsible for preparing the body to ...

Other Biology News:EPA to study Puerto Rico waters and marine habitat 2 From stem cells to new organs: Stanford and NYU scientists cross threshold in regenerative medicine 2 Researchers capture wave of brain activity linked to anticipation 2

EPA to study Puerto Rico waters and marine habitat From stem cells to new organs: Stanford and NYU scientists cross threshold in regenerative medicine Researchers capture wave of brain activity linked to anticipation

Request Info...

... ,ICC and IHC Protocol Development ,Antibody ... Screenings in Animal or Human Cells ... Cells and Tissues ,Peroxidase, Alkaline Phosphatase, ... or Electron Microscopy ,Protein Localization in ...

Biology Products:

Morphine ELISA Kit, Single from Bio-Quant Inc.PCP ELISA Kit, Single from Bio-Quant Inc.Cotinine ELISA Kit, Single from Bio-Quant Inc.Immunodetection of Specific Proteins from QualTek Molecular Laboratories

Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License...(angamo is also developing sequence-speci...)